Patents Assigned to Aptinyx, Inc.
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10052308
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 21, 2018
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9932347
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 3, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9925169
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 27, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9828384
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 28, 2017
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9758525
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: September 12, 2017
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9738650
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: August 22, 2017
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9579304
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: February 28, 2017
    Assignee: Aptinyx, Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9512134
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: December 6, 2016
    Assignee: Aptinyx, Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9504670
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Aptinyx, Inc.
    Inventors: John A. Lowe, III, M. Amin Khan